RxDoctor Payments Data

Shannon Bernbaum

Physician Assistant · Houston, TXNPI 1891280988

Payments from drug & device makers

$3,595in general payments, 2019–2025

Across 180 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$647
  • AbbVie$643
  • Sumitomo Pharma America, Inc.$432
  • Astellas Pharma US Inc$415
  • Novo Nordisk$232
  • Urovant Sciences Inc$191
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$38011%
  • Food & beverage$3,06185%
  • Education$1554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,595 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron131$86,819
MyrbetriqMirabegron86$55,578
Estradiol194$15,822
Mirabegron ErMirabegron14$8,885
ImvexxyEstradiol32$6,996
Cefpodoxime Proxetil81$3,677
Trospium Chloride ErTrospium Chloride13$2,897
Fosfomycin Tromethamine18$2,547
Methenamine Hippurate16$2,300
Trimethoprim28$1,521
YuvafemEstradiol11$1,444
Cephalexin85$972
Clobetasol Propionate36$958
Doxycycline Hyclate53$897
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$432$86,819131 claims
Astellas Pharma US IncMyrbetriq$415$55,57886 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →